Aktie A12EZQ ZIVO BIOSCIENCE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen ZIVO Bioscience, Inc. Other OTC

Aktien

A12EZQ

US98978N1019

ZIVO

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
ZIVO Bioscience Announces Uplisting to OTCQB Market
Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding
ZIVO Bioscience, Inc. announced that it expects to receive $0.531142 million in funding
ZIVO Bioscience, Inc. announced that it has received $0.308936 million in funding
ZIVO Bioscience, Inc. announced that it expects to receive $0.308936 million in funding
ZIVO Bioscience, Inc. announced that it has received $0.2 million in funding
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from S&P TMI Index
ZIVO Bioscience, Inc.(OTCPK:ZIVO) dropped from NASDAQ Composite Index
ZIVO Bioscience, Inc. announced that it expects to receive $0.15 million in funding
ZIVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Zivo Bioscience Insider Bought Shares Worth $199,600, According to a Recent SEC Filing
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Announces Reverse Stock Split
ZIVO Bioscience : Dawon James Small Cap Growth Conference Presentation
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EURV Aktie
  4. A12EZQ Aktie
  5. Nachrichten ZIVO Bioscience, Inc.
  6. Andere Sprachen